HC Wainwright Reiterates Buy Rating on BioCryst Pharmaceuticals, Eyes $32 Target
HC Wainwright maintains its buy rating on BioCryst Pharmaceuticals with a $32 price target, a 220% upside from the current price.
Key Points
- HC Wainwright reiterated its buy rating on BioCryst Pharmaceuticals with a $32 price target on June 30, 2026, as shares traded at $9.55.
- HC Wainwright's $32 price target implies 220% upside from BioCryst Pharmaceuticals, Inc.'s ($BCRX) current $10 share price.
- BioCryst Pharmaceuticals holds a market cap of approximately $2.53 billion, with a forward P/E ratio of 14.62 and a 52-week range between $6.00 and $10.94.
- Insider buying activity was noted on June 11, 2026, with several insiders acquiring shares, while analysts like Cantor Fitzgerald also maintain a buy rating on the stock.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 30, 2026, HC Wainwright reiterated its buy rating on BioCryst Pharmaceuticals, Inc. (NasdaqGS: BCRX) and set a price target of $32. This comes as the stock traded around $9.55 on Tuesday.
HC Wainwright & Co. vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Analysts Set New Price Targets
HC Wainwright & Co. maintained its buy rating on BioCryst Pharmaceuticals, setting a price target of $32 on June 30, 2026. Cantor Fitzgerald also maintained a buy rating with a target of $29 on the same day. Other analysts such as Citizens and Wedbush have previously set buy ratings with targets of $28 and $21, respectively.
BioCryst Pharmaceuticals, Inc. Stock Up 1.8%
Shares of NasdaqGS:BCRX traded near $9.55 on Tuesday. BioCryst Pharmaceuticals has a market cap of approximately $2.53 billion and a forward P/E ratio of 14.62. The stock has shown a 52-week low of $6.00 and a high of $10.94, with a 50-day moving average of $8.92 and a 200-day moving average of $7.97. The company maintains a current ratio of 1.91 and a quick ratio of 1.78.
$BCRX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at BioCryst Pharmaceuticals, Inc.
On June 11, 2026, several insiders at BioCryst Pharmaceuticals were involved in buying activity. Steven Galson, Machelle Sanders, Steven Frank, and Theresa Heggie each acquired shares, with the transactions not being part of a planned trading program.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc. is a biotechnology company based in Durham, North Carolina. It focuses on developing and commercializing medicines for rare diseases, including hereditary angioedema (HAE). The company offers products like RAPIVAB for influenza and ORLADEYO for HAE. Founded in 1986, BioCryst continues to work on various treatments in different phases of clinical trials.
Bottom Line
Investors are keeping a close eye on BioCryst Pharmaceuticals as HC Wainwright reiterates its buy rating with a $32 target. The stock's recent trading activity and insider buying could be of interest to market watchers. As always, it's important to remember that analyst ratings are based on current assessments and can change over time.
Get BioCryst Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $BCRX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.